Background: Most of the reports on tumor relapse are recurrence of the same type of tumor after months to few years of a successful initial cancer treatment. It is generally unusual and unexpected that a different type of the second tumor occurs after several decades of the curative treatment of the original tumor. Case Presentation: We report a case of 74-year-old man with intrahepatic cholangiocarcinoma (ICC) diagnosed 38 years after curative resection of hepatocellular carcinoma (HCC). In addition to the uniqueness of longer survival and developed a new type of tumor, both the original HCC and the later occurred ICC were detected through a cancer surveillance program by screening alpha-fetoprotein (AFP) and ultrasonography of the liver for the general population and/or high risk group of people who were asymptomatic. Conclusion: This report provides evidence demonstrating occurrence of new type of tumor following initial curative therapy of the original tumor. In addition, this case report also highlights the importance of cancer surveillance program for earlier detection of the tumors to achieve a remarkably improved prognosis of the cancer patients for a prolonged cancer free survival time.
Cite this paper
J. Chen, W. Lu, L. Wang, Y. Zhang, N. Wang, Y. Chen, J. Zhu, H. Zheng, J. Yang and F. Chen, "Cholangiocarcinoma Arising 38 Years after Surgical Resection of Hepatocellular Carcinoma," Journal of Cancer Therapy, Vol. 4 No. 5, 2013, pp. 953-956. doi: 10.4236/jct.2013.45107.
 F. Chen, K. Beezhold and V. Castranova, “JNK1, a Potential Therapeutic Target for Hepatocellular Carcinoma,” Biochimica et Biophysica Acta, Vol. 1796, No. 2, 2009, pp. 242-251.
 I. Ikai, S. Arii, T. Ichida, K. Okita, M. Omata, M. Kojiro, K. Takayasu, Y. Nakanuma, M. Makuuchi and Y. Matsuyama, et al., “Report of the 16th Follow-Up Survey of Primary Liver Cancer,” Hepatology Research, Vol. 32, No. 3, 2005, pp. 163-172.
 J. G. Chen, D. M. Parkin, Q. G. Chen, J. H. Lu, Q. J. Shen, B. C. Zhang and Y. R. Zhu, “Screening for Liver Cancer: Results of a Randomised Controlled Trial in Qidong, China,” Journal of Medical Screening, Vol. 10, No. 4, 2003, pp. 204-209. doi:10.1258/096914103771773320
 J. G. Chen and S. W. Zhang, “Liver Cancer Epidemic in China: Past, Present and Future,” Seminars in Cancer Biology, Vol. 21, No. 1, 2011, pp. 59-69.
 T. W. Kensler, G. S. Qian, J. G. Chen and J. D. Groopman, “Translational Strategies for Cancer Prevention in Liver,” Nature Reviews Cancer, Vol. 3, No. 5, 2003, pp. 321-329. doi:10.1038/nrc1076
 C. H. Lee, C. J. Chang, Y. J. Lin, C. N. Yeh, M. F. Chen and S. Y. Hsieh, “Viral Hepatitis-Associated Intrahepatic Cholangiocarcinoma Shares Common Disease Processes with Hepatocellular Carcinoma,” British Journal of Cancer, Vol. 100, No. 11, 2009, pp. 1765-1770.
 Q. Chang, Y. Zhang, K. J. Beezhold, D. Bhatia, H. Zhao, J. Chen, V. Castranova, X. Shi and F. Chen, “Sustained JNK1 Activation Is Associated with Altered Histone H3 Methylations in Human Liver Cancer,” Journal of Hepatology, Vol. 50, No. 2, 2009, pp. 323-333.
 F. Chen, S. Li and V. Castranova, “Overlapping Signature Genes between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma,” European Journal of Gastroenterology & Hepatology, Vol. 21, No. 11, 2009, pp. 1320-1321. doi:10.1097/MEG.0b013e32832b2123
 T. M. Welzel, L. Mellemkjaer, G. Gloria, L. C. Sakoda, A. W. Hsing, L. El Ghormli, J. H. Olsen and K. A. McGlynn, “Risk Factors for Intrahepatic Cholangiocarcinoma in a Low-Risk Population: A Nationwide CaseControl Study,” International Journal of Cancer, Vol. 120, No. 3, 2007, pp. 638-641. doi:10.1002/ijc.22283
 F. Chen, “JNK-Induced Apoptosis, Compensatory Growth, and Cancer Stem Cells,” Cancer Research, Vol. 72, No. 2, 2012, pp. 379-386.
 S. A. Khan, H. C. Thomas, B. R. Davidson and S. D. Taylor-Robinson, “Cholangiocarcinoma,” Lancet, Vol. 366, No. 9493, 2005, pp. 1303-1314.